Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

Details Acyloxyalkyl carbamate prodrugs, methods of synthesis and use Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

2006-09-19

2006-09-19

Zucker, Paul A. (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C560S024000

Reexamination Certificate

active

07109239

ABSTRACT:
The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

REFERENCES:
patent: 2996431 (1961-08-01), Barry
patent: 3139383 (1964-06-01), Neville
patent: 3402240 (1968-09-01), Cain et al.
patent: 3471548 (1969-10-01), Keberle et al.
patent: 3634428 (1972-01-01), Keberle et al.
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4036829 (1977-07-01), Ferres et al.
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4094992 (1978-06-01), Kaplan et al.
patent: 4126684 (1978-11-01), Robson et al.
patent: 4200098 (1980-04-01), Ayer et al.
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4421736 (1983-12-01), Walters
patent: 4434153 (1984-02-01), Urquhart et al.
patent: 4721613 (1988-01-01), Urquhart et al.
patent: 4752470 (1988-06-01), Mehta
patent: 4760057 (1988-07-01), Alexander
patent: 4816263 (1989-03-01), Ayer et al.
patent: 4820523 (1989-04-01), Shtohryn et al.
patent: 4853229 (1989-08-01), Theeuwes
patent: 4916230 (1990-04-01), Alexander
patent: 4996058 (1991-02-01), Sinnreich et al.
patent: 5006560 (1991-04-01), Kreutner
patent: 5091184 (1992-02-01), Khanna
patent: 5229135 (1993-07-01), Philipon
patent: 5466811 (1995-11-01), Alexander
patent: 5684018 (1997-11-01), Alexander
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5719185 (1998-02-01), Bountra et al.
patent: 5773592 (1998-06-01), Mills
patent: 6051734 (2000-04-01), Wildervanck et al.
patent: 6117908 (2000-09-01), Andrews et al.
patent: 6375987 (2002-04-01), Farah et al.
patent: 6379700 (2002-04-01), Joachim et al.
patent: 6627223 (2003-09-01), Percel et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2003/0171303 (2003-09-01), Gallop et al.
patent: 2003/0176398 (2003-09-01), Gallop et al.
patent: 2003/0228644 (2003-12-01), Mills
patent: 2004/0006132 (2004-01-01), Gallop et al.
patent: 2004/0014940 (2004-01-01), Raillard et al.
patent: 4224342 (1994-01-01), None
patent: 4424975 (1996-01-01), None
patent: 0130119 (1984-06-01), None
patent: 0463969 (1995-02-01), None
patent: 1178034 (2002-02-01), None
patent: 01319466 (1989-12-01), None
patent: WO 98/22110 (1998-05-01), None
patent: WO 01/08675 (2001-02-01), None
patent: WO 01/2638 (2001-04-01), None
patent: WO 01/26638 (2001-04-01), None
patent: WO 01/90052 (2001-11-01), None
patent: WO 02/096404 (2002-12-01), None
patent: WO 02/100347 (2002-12-01), None
patent: WO 02/100347 (2002-12-01), None
patent: WO 03/011255 (2003-02-01), None
Alderman, “A Review of Cellulose Ethers in Hydrophilic Matrices or Oral controlled-Release Dosage Forms,”Int. J. Pharm. Tech.&Prod. Mfr.1984, 5(3) 1-9.
Astudillo et al., “A Very Simple Oxidation of Olefins and Ketones with UHP-Maleic Anhydride,”Heterocycles1993, 36, 1075-1080.
Balicki et al., “Mild and Efficient Conversion of Nitriles to Amides with Basic Urea-Hydrogen Peroxide Adduct,”Synth. Commun.1993, 23, 3149.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm.1979, 2, 307.
Berthelot et al., “3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABABreceptor studies,”J. Med. Chem.1991, 34, 2557-2560.
Berthelot et al., “Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABABsites,”J. Med. Chem.1987, 30, 743-746.
Bowery, “GABABreceptors and their significance in mammalian pharmacology,”Trends Pharmacol. Sci.1989, 10, 401-407.
Butcher “Carbamate Esters: a Simple, Mild Method of Formation,”SynLett, 1994, 825-826.
Cercos-Fortea et al., “Influence Of Leucine On Intestinal Baclofen Absorption As A Model Compound Of Neutral Alpha-Aminoacids,”Biopharm. Drug. Disp.1995, 16, 563-577.
Chenevert et al., “Chemoenzymatic Synthesis of Both Enantiomers of Baclofen,”Tetrahedron Lett.1991, 32, 4249-4250.
Ciccaglione et al., “Effect of Acute and Chronic Administration of the GABABAgonist Baclofen on 24 hour pH metry and Symptoms in Control Subjects and in Patients with Gastro-oesophageal Reflux Disease,”Gut2003, 52, 464-470.
Coleman et al., “Polymer Review: A Practical Guide to Polymer Miscibility,”Polymers1990, 31, 1187-1231.
Cooper et al., “Oxidation Reactions Using Urea-Hydrogen Peroxide: A Safe Alternative to Anhydrous Hydrogen Peroxide,”Synlett.1990, 533-535.
Deguchi et al., “Study on Brain Interstitial Fluid Distribution and Blood-brain Barrier Transport of Baclofen in Rats by Microdialysis,”Pharm. Res.1995. 12, 1838-1844.
During et al., “Controlled Release of Dopamine from a Polymeric Brain implant:in vivoCharacterization,” 1989,Ann. Neurol.25:351.
Fincher, “Particle Size of Drugs and Its Relationship to Absorption and Activity,”J. Pharm. Sci.1968, 57, 1825-1835.
Fromm et al., “Comparison of L-Baclofen and Racemic Baclofen in Trigeminal Neuralgia,”Neurology1987, 37, 1725-1728.
Goodson, “Medical Applications of Controlled Release,” vol. 2, pp. 115-138 (1984).
Guillon et al., “Pharmacological Evaluation of New Baclofen Derivatives,”Pharm. Pharmacol. Commun.1999, 5, 243-247.
Herdeis et al., “Synthesis of Homochiral R-Baclofen from S-Glutamic Acid,”Tetrahedron Asymmetry1992, 3, 1213-1221.
Hoes et al., “The Application of Drug-Polymer Conjugates in Chemotherapy,”Drug Carrier Systems1989, 9, 57-110.
Howard et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg.1989 71(1):105-112.
Krach, “Pharmacotherapy Of Spasticity: Oral Medications And Intrathecal Baclofen,”J. Child Neurol.2001, 16, 31-36.
Katz, “Management of Spasticity,”Am. J. Phys. Med. Rehabil.1988, 2, 108-116.
Kayser et al., “Designer Yeast: an Enantioselective Oxidizing Reagent for Organic Synthesis,”SynLett ,1999, 1:153.
Krogsgaard-Larsen, “GABA Synaptic Mechanisms: Stereochemical And Conformational Requirements,”Med. Res. Rev.1988, 8, 27-56.
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,”J Macromol. Sci. Rev. Macromol Chem.1983, 23:61.
Langer, “New Method of Drug Delivery,” 1990,Science249:1527-1533.
Leisen et al., “Lipophilicities of Baclofen Ester Prodrugs Correlate with Affinities to the ATP-dependent Efflux Pump P-glycoprotein: Relevance for their Permeation Across the Blood-brain Barrier,”Pharm. Res.2003, 20, 772-778.
Leong et al., “Polymeric Controlled Drug Delivery,”Adv. Drug Delivery Rev.1987, 1, 199-233.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science1985 228: 190-192.
List et al., “The Proline-catalyzed Direct Asymmetric Three-component Mannich Reaction: Scope, Optimization, and Application to the Highly Enantioselective Synthesis o

Affiliated with

Also associated with

Rating

Acyloxyalkyl carbamate prodrugs, methods of synthesis and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acyloxyalkyl carbamate prodrugs, methods of synthesis and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acyloxyalkyl carbamate prodrugs, methods of synthesis and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3572143